{"id":"NCT00105534","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)","officialTitle":"A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0 % AzaSite Compared to Vehicle in the Treatment of Bacterial Conjunctivitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-07","primaryCompletion":"2006-01","completion":"2006-01","firstPosted":"2005-03-16","resultsPosted":"2011-10-27","lastUpdate":"2013-11-21"},"enrollment":685,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Bacterial Conjunctivitis"],"interventions":[{"type":"DRUG","name":"AzaSite","otherNames":[]},{"type":"OTHER","name":"Vehicle","otherNames":[]}],"arms":[{"label":"AzaSite","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"SHAM_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the clinical and microbial efficacy and safety of AzaSite compared to vehicle for bacterial conjunctivitis. Adults and children one year of age and older with bacterial conjunctivitis in at least one eye may be eligible. Subjects will be randomly assigned to receive either 1.0 % AzaSite or Vehicle. Three visits will be required for this study.","primaryOutcome":{"measure":"Participants Who Achieved Clinical Resolution","timeFrame":"Visit 3 (Days 6-7)","effectByArm":[{"arm":"AzaSite","deltaMin":82,"sd":null},{"arm":"Vehicle","deltaMin":74,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":32,"countries":["United States"]},"refs":{"pmids":["18374301"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":333},"commonTop":[]}}